Literature DB >> 24804816

Expression of matrix metalloproteinase-2 and 9 in cervical intraepithelial neoplasia and cervical carcinoma among different age groups of premenopausal and postmenopausal women.

Arnab Ghosh1, Anuradha Moirangthem, Rabindranath Dalui, TapanKumar Ghosh, Arghya Bandyopadhyay, Anindya Dasgupta, Uma Banerjee, Narayan Jana, Anupam Basu.   

Abstract

PURPOSE: The objective was to study the gelatinolytic activity of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in preinvasive and invasive carcinoma of the uterine cervix. The expressions were analysed against different age groups, as to demonstrate whether the expression of MMP-2 and MMP-9 is an early or a late event during the progression of cervical cancer. Additionally, the diagnostic accuracy of MMP-2 and MMP-9 was evaluated with ROC curve.
METHODS: A total number of 180 samples of cervical tissue were studied for MMP-2 and MMP-9 gelatinolytic activity. The cases were selected as to include 63 normal cases, 94 CIN cases and 23 cervical carcinoma cases. Among 94 CIN cases, 40 were CIN1, 26 were CIN2 and 28 were CIN3, as reported by histopathology. The gelatinolytic activities of MMP-2 and MMP-9 were evaluated by gelatin zymography in premenopausal and postmenopausal groups.
RESULTS: MMP-2 expressions (latent and active) were very low in control samples, followed by increase in CIN1, decrease in CIN2 and further increase in advance stages. MMP-9 had also shown the same expression pattern that of MMP-2. While comparing the expression of MMP-2 and MMP-9 in different age groups, we found initial CIN stages were prevalent in early age that expressed considerable amount of MMP-2 and MMP-9, and advance stages of carcinoma cervix were prevalent at an elderly age.
CONCLUSION: Both MMP-2 and MMP-9 have role in cancer progression and remodelling of the ectocervix. Although expression level varies intricately, a distinctive ROC curve demonstrated MMP-2 active form and MMP-9 form could be used in diagnostic purpose in detection of cervical lesion and cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24804816     DOI: 10.1007/s00432-014-1695-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

1.  Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.

Authors:  Maiken Thyregod Joergensen; Nils Brünner; Ove B Schaffalitzky De Muckadell
Journal:  Anticancer Res       Date:  2010-02       Impact factor: 2.480

2.  Matrix metalloproteinase 9 in the uterine cervix during tumor progression.

Authors:  A Talvensaari-Mattila; T Turpeenniemi-Hujanen
Journal:  Int J Gynaecol Obstet       Date:  2005-10-17       Impact factor: 3.561

Review 3.  Matrix metalloproteinases (MMPs) in health and disease: an overview.

Authors:  Charles J Malemud
Journal:  Front Biosci       Date:  2006-05-01

Review 4.  Molecular aspects of tumor cell invasion and metastasis.

Authors:  S Aznavoorian; A N Murphy; W G Stetler-Stevenson; L A Liotta
Journal:  Cancer       Date:  1993-02-15       Impact factor: 6.860

5.  Matrix metalloproteinase-9 expression is increased in astrocytic glioma and associated with prognosis of patients.

Authors:  Jipei Zhao; Gang Li; Zhenwei Zhao; Jun Wang; Guodong Gao; Shiming He
Journal:  Jpn J Clin Oncol       Date:  2012-09-12       Impact factor: 3.019

6.  Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.

Authors:  B Davidson; I Goldberg; J Kopolovic; L Lerner-Geva; W H Gotlieb; B Weis; G Ben-Baruch; R Reich
Journal:  Gynecol Oncol       Date:  1999-03       Impact factor: 5.482

7.  Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP.

Authors:  Ravikumar Aalinkeel; Bindukumar B Nair; Jessica L Reynolds; Donald E Sykes; Supriya D Mahajan; Kailash C Chadha; Stanley A Schwartz
Journal:  Immunol Invest       Date:  2011-03-10       Impact factor: 3.657

8.  Metalloproteinase 2 and 9 activity in the development of pancreatic cancer.

Authors:  Marek Durlik; Katarzyna Gardian
Journal:  Pol Przegl Chir       Date:  2012-08

9.  A matrix metalloproteinase expressed on the surface of invasive tumour cells.

Authors:  H Sato; T Takino; Y Okada; J Cao; A Shinagawa; E Yamamoto; M Seiki
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

10.  Differences in expression of tumor markers between pre- and postmenopausal women with invasive cervical cancer.

Authors:  Dan Hellberg; Tibor Tot; Ulf Stendahl
Journal:  Anticancer Res       Date:  2008 May-Jun       Impact factor: 2.480

View more
  6 in total

Review 1.  High Resolution Proteomic Analysis of the Cervical Cancer Cell Lines Secretome Documents Deregulation of Multiple Proteases.

Authors:  Kalliopi I Pappa; Georgia Kontostathi; Manousos Makridakis; Vasiliki Lygirou; Jerome Zoidakis; George Daskalakis; Nicholas P Anagnou
Journal:  Cancer Genomics Proteomics       Date:  2017 Nov-Dec       Impact factor: 4.069

2.  Correlation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinoma.

Authors:  Lu-Lu Zhai; Chong-Yang Cai; Yang Wu; Zhi-Gang Tang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Praeruptorin A Inhibits Human Cervical Cancer Cell Growth and Invasion by Suppressing MMP-2 Expression and ERK1/2 Signaling.

Authors:  Min-Hua Wu; Chia-Liang Lin; Hui-Ling Chiou; Shun-Fa Yang; Ching-Yi Lin; Chung-Jung Liu; Yi-Hsien Hsieh
Journal:  Int J Mol Sci       Date:  2017-12-21       Impact factor: 5.923

4.  Construction and Evaluation of the Tumor-Targeting, Cell-Penetrating Multifunctional Molecular Probe iCREKA.

Authors:  Li-Juan Wang; Hong-Sheng Li; Quan-Shi Wang; Hu-Bing Wu; Yan-Jiang Han; Wen-Lan Zhou; Meng Wang; Shun Huang
Journal:  Contrast Media Mol Imaging       Date:  2018-03-04       Impact factor: 3.161

5.  Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.

Authors:  Emilia Lubowicka; Monika Zbucka-Kretowska; Iwona Sidorkiewicz; Monika Zajkowska; Ewa Gacuta; Andrzej Puchnarewicz; Lech Chrostek; Maciej Szmitkowski; Sławomir Ławicki
Journal:  Pathol Oncol Res       Date:  2019-02-28       Impact factor: 3.201

6.  IWR-1 inhibits epithelial-mesenchymal transition of colorectal cancer cells through suppressing Wnt/β-catenin signaling as well as survivin expression.

Authors:  Sang Chul Lee; Ok-Hee Kim; Sang Kuon Lee; Say-June Kim
Journal:  Oncotarget       Date:  2015-09-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.